Express Scripts Stock Price, News & Analysis (NASDAQ:ESRX)

$75.23 +1.16 (+1.57 %)
(As of 02/20/2018 10:24 AM ET)
Previous Close$75.23
Today's Range$74.11 - $75.64
52-Week Range$55.80 - $83.49
Volume3.14 million shs
Average Volume4.21 million shs
Market Capitalization$42.61 billion
P/E Ratio12.50
Dividend YieldN/A
Beta0.93

About Express Scripts (NASDAQ:ESRX)

Express Scripts logoExpress Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segment’s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segment’s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Health Care Plans
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Debt-to-Equity Ratio0.86%
Current Ratio0.73%
Quick Ratio0.61%

Price-To-Earnings

Trailing P/E Ratio12.4966777408638
Forward P/E Ratio10.69
P/E Growth0.81

Sales & Book Value

Annual Sales$100.29 billion
Price / Sales0.42
Cash Flow$10.04 per share
Price / Cash7.49
Book Value$26.34 per share
Price / Book2.86

Profitability

Trailing EPS$6.02
Net Income$3.40 billion
Net Margins3.64%
Return on Equity25.46%
Return on Assets7.95%

Miscellaneous

Employees25,600
Outstanding Shares566,370,000

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts declared that its board has authorized a stock buyback program on Wednesday, December 20th 2017, which allows the company to repurchase 45,000,000 shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts Holding (NASDAQ:ESRX) released its quarterly earnings data on Tuesday, October, 24th. The company reported $1.90 EPS for the quarter, hitting the consensus estimate of $1.90. The firm earned $24.68 billion during the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. Express Scripts's revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.74 EPS. View Express Scripts' Earnings History.

When will Express Scripts make its next earnings announcement?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Express Scripts.

Where is Express Scripts' stock going? Where will Express Scripts' stock price be in 2018?

18 analysts have issued 1-year price targets for Express Scripts' shares. Their forecasts range from $57.00 to $95.00. On average, they anticipate Express Scripts' stock price to reach $79.27 in the next twelve months. View Analyst Ratings for Express Scripts.

Are investors shorting Express Scripts?

Express Scripts saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 20,899,812 shares, a drop of 9.1% from the January 12th total of 22,990,876 shares. Based on an average daily volume of 4,388,271 shares, the short-interest ratio is currently 4.8 days. Currently, 3.7% of the shares of the company are short sold.

Who are some of Express Scripts' key competitors?

Who owns Express Scripts stock?

Express Scripts' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.28%), Barrow Hanley Mewhinney & Strauss LLC (3.02%), Macquarie Group Ltd. (1.80%), Bank of New York Mellon Corp (1.46%), Geode Capital Management LLC (1.17%) and LSV Asset Management (0.87%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Who sold Express Scripts stock? Who is selling Express Scripts stock?

Express Scripts' stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, APG Asset Management N.V., BlackRock Inc., Brown Advisory Inc., Macquarie Group Ltd., American Century Companies Inc., Boston Partners and OppenheimerFunds Inc.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Who bought Express Scripts stock? Who is buying Express Scripts stock?

Express Scripts' stock was bought by a variety of institutional investors in the last quarter, including Swedbank, ValueAct Holdings L.P., Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Two Sigma Investments LP, Bank of New York Mellon Corp, Schroder Investment Management Group and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Express Scripts.

How do I buy Express Scripts stock?

Shares of Express Scripts can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of Express Scripts stock can currently be purchased for approximately $75.23.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $42.61 billion and generates $100.29 billion in revenue each year. The company earns $3.40 billion in net income (profit) each year or $6.02 on an earnings per share basis. Express Scripts employs 25,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  684 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  1,147
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Express Scripts (NASDAQ:ESRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.202.052.11
Ratings Breakdown: 4 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.27$78.38$69.00$69.73
Price Target Upside: 0.05% downside2.13% downside12.82% upside15.61% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2018Royal Bank of CanadaUpgradeSector Perform -> Outperform$68.00LowView Rating Details
1/30/2018Sanford C. BernsteinDowngradeMarket Perform -> Underperform$55.80 -> $77.50LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$86.00LowView Rating Details
1/12/2018SunTrust BanksReiterated RatingBuy$95.00LowView Rating Details
1/9/2018Robert W. BairdReiterated RatingOutperform -> Buy$81.00 -> $92.00N/AView Rating Details
1/4/2018Evercore ISIInitiated CoverageIn -> In-Line$78.00LowView Rating Details
12/21/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
12/15/2017Jefferies GroupSet Price TargetBuy$80.00HighView Rating Details
12/15/2017Raymond James FinancialReiterated RatingSellLowView Rating Details
12/14/2017Maxim GroupBoost Price TargetBuy$78.00 -> $87.00LowView Rating Details
12/4/2017Deutsche BankInitiated CoverageBuy$75.00HighView Rating Details
8/10/2017Morgan StanleyBoost Price TargetUnderweight$52.00 -> $57.00LowView Rating Details
6/9/2017CowenReiterated RatingOutperform$83.00LowView Rating Details
4/26/2017Edward JonesDowngradeBuy -> HoldHighView Rating Details
4/25/2017Bank of AmericaReiterated RatingNeutral$77.00HighView Rating Details
3/29/2017ArgusReiterated RatingHoldLowView Rating Details
3/15/2017Wells Fargo & CoDowngradeMarket Perform -> UnderperformLowView Rating Details
3/8/2017Leerink SwannReiterated RatingMarket Perform$75.00LowView Rating Details
2/16/2017Credit Suisse GroupReiterated RatingBuy$85.00N/AView Rating Details
2/14/2017OppenheimerReiterated RatingHoldN/AView Rating Details
12/16/2016BarclaysReiterated RatingOverweightN/AView Rating Details
6/1/2016WedbushReiterated RatingNeutralN/AView Rating Details
5/24/2016CitigroupReiterated RatingBuyN/AView Rating Details
4/27/2016FBR & CoLower Price TargetMkt Perform$90.00 -> $75.00N/AView Rating Details
3/18/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$2.08N/AView Earnings Details
10/24/2017Q3 2017$1.90$1.90$25.68 billion$24.68 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.71$1.73$25.52 billion$25.35 billionViewN/AView Earnings Details
4/24/2017Q1 17$1.32$1.33$24.95 billion$24.65 billionViewN/AView Earnings Details
2/14/2017Q4 2016$1.87$1.88$26.31 billion$24.90 billionViewListenView Earnings Details
10/25/2016Q3$1.74$1.74$25.48 billion$25.41 billionViewListenView Earnings Details
7/25/2016Q216$1.57$1.57$25.42 billion$25.20 billionViewListenView Earnings Details
4/25/2016Q1$1.22$1.22$25.20 billion$24.80 billionViewListenView Earnings Details
2/16/2016Q4$1.56$1.56$26.58 billion$26.18 billionViewListenView Earnings Details
10/27/2015Q315$1.44$1.45$26.38 million$25.22 millionViewListenView Earnings Details
7/28/2015Q215$1.40$1.44$26.13 billion$25.45 billionViewListenView Earnings Details
4/28/2015Q115$1.10$1.10$24.34 billion$24.90 billionViewListenView Earnings Details
2/23/2015Q414$1.38$1.39$25.68 billion$26.31 billionViewListenView Earnings Details
10/28/2014Q314$1.29$1.29$24.93 billion$25.78 billionViewListenView Earnings Details
7/29/2014Q214$1.22$1.23$24.42 billion$25.11 billionViewListenView Earnings Details
4/29/2014Q114$1.01$0.99$23.81 billion$23.69 billionViewListenView Earnings Details
2/20/2014Q413$1.12$1.12$25.49 billion$25.78 billionViewN/AView Earnings Details
10/25/2013Q313$1.08$1.08$25.01 billion$25.92 billionViewListenView Earnings Details
7/29/2013Q2 2013$1.10$1.12$25.51 billion$26.40 billionViewListenView Earnings Details
4/29/2013Q1 2013$0.97$0.99$25.55 billion$26.06 billionViewListenView Earnings Details
2/18/2013Q4 2012$1.04$1.05$27.24 billion$27.41 billionViewListenView Earnings Details
11/5/2012Q312$0.99$1.02$27.48 billion$27.00 billionViewN/AView Earnings Details
8/7/2012$0.82$0.88ViewN/AView Earnings Details
5/10/2012$0.77$0.73ViewN/AView Earnings Details
2/22/2012$0.85$0.82ViewN/AView Earnings Details
10/25/2011$0.77$0.79ViewN/AView Earnings Details
7/21/2011$0.69$0.71ViewN/AView Earnings Details
4/26/2011$0.69$0.66ViewN/AView Earnings Details
2/16/2011$0.70$0.71ViewN/AView Earnings Details
10/27/2010Q3 2010$0.65$0.65ViewN/AView Earnings Details
7/28/2010Q2 2010$0.59$0.60ViewN/AView Earnings Details
4/28/2010Q1 2010$0.55$0.55ViewN/AView Earnings Details
2/24/2010Q4 2009$0.45$0.49ViewN/AView Earnings Details
10/28/2009Q3 2009$0.41$0.40ViewN/AView Earnings Details
7/29/2009Q2 2009$0.44$0.44ViewN/AView Earnings Details
4/29/2009Q1 2009$0.41$0.43ViewN/AView Earnings Details
2/25/2009Q4 2008$0.42$0.41ViewN/AView Earnings Details
10/30/2008Q3 2008$0.39$0.41ViewN/AView Earnings Details
7/30/2008Q2 2008$0.36$0.38ViewN/AView Earnings Details
4/29/2008Q1 2008$0.34$0.35ViewN/AView Earnings Details
2/21/2008Q4 2007$0.32$0.34ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2018 EPS Consensus Estimate: $8.37
2019 EPS Consensus Estimate: $9.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.46$1.93$1.65
Q2 20185$1.86$2.37$2.06
Q3 20185$2.04$2.45$2.22
Q4 20185$2.26$2.68$2.44
Q1 20192$1.58$2.17$1.88
Q2 20192$2.09$2.49$2.29
Q3 20192$2.26$2.68$2.47
Q4 20191$2.95$2.95$2.95
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Express Scripts (NASDAQ:ESRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 86.45%
Insider Trades by Quarter for Express Scripts (NASDAQ:ESRX)
Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Glen D StettinVPSell3,449$81.00$279,369.0033,715View SEC Filing  
1/2/2018Glen D StettinVPSell3,448$76.00$262,048.00View SEC Filing  
12/15/2017Christine HoustonVPSell10,104$70.08$708,088.3287,400View SEC Filing  
11/1/2017Phyllis S. AndersonVPSell643$62.37$40,103.91View SEC Filing  
10/31/2017Timothy C WentworthCEOBuy8,000$61.13$489,040.0098,628View SEC Filing  
9/11/2017Woodrow A Myers JrDirectorSell3,900$63.93$249,327.0011,500View SEC Filing  
9/8/2017Phyllis S AndersonVPSell578$63.13$36,489.1410,530View SEC Filing  
8/23/2017Everett NevilleVPSell1,163$61.48$71,501.2418,232View SEC Filing  
5/19/2017Phyllis S AndersonVPSell1,100$60.08$66,088.0011,108View SEC Filing  
3/1/2017Everett NevilleSVPSell2,352$70.16$165,016.3211,287View SEC Filing  
1/3/2017Everett NevilleVPSell1,123$69.41$77,947.4312,712View SEC Filing  
9/14/2016Woodrow A Myers JrDirectorSell12,036$70.40$847,334.4014,918View SEC Filing  
9/12/2016Christopher A McginnisVPSell1,785$70.77$126,324.454,955View SEC Filing  
5/10/2016Everett NevilleVPSell800$74.11$59,288.0013,835View SEC Filing  
4/29/2016Mahon Thomas P MacDirectorSell5,482$73.93$405,284.2655,689View SEC Filing  
3/10/2016Christopher A McginnisVPSell579$68.56$39,696.246,508View SEC Filing  
3/7/2016Phyllis S AndersonVPSell614$71.14$43,679.964,346View SEC Filing  
2/29/2016Everett NevilleVPSell4,323$71.00$306,933.0011,126View SEC Filing  
6/9/2015Gary WimberlyVPSell1,644$87.14$143,258.16View SEC Filing  
6/1/2015Gary WimberlyVPSell46,069$86.15$3,968,844.35View SEC Filing  
3/2/2015Glen D StettinVPSell2,674$84.39$225,658.86View SEC Filing  
2/25/2015Glen D StettinVPSell27,603$87.55$2,416,642.65View SEC Filing  
12/2/2014Keith J EblingVPSell10,000$84.25$842,500.00View SEC Filing  
12/1/2014Steven B MillerVPSell4,896$83.57$409,158.72View SEC Filing  
11/28/2014Glen D StettinVPSell10,800$82.96$895,968.00View SEC Filing  
11/17/2014John O ParkerDirectorSell25,822$78.75$2,033,482.50View SEC Filing  
11/7/2014Maura C BreenDirectorSell13,128$77.80$1,021,358.40View SEC Filing  
9/5/2014Edward B IgnaczakEVPSell9,886$75.28$744,218.08View SEC Filing  
8/28/2014Seymour SternbergDirectorSell15,508$74.12$1,149,452.96View SEC Filing  
8/25/2014Keith J EblingVPSell10,000$75.50$755,000.00View SEC Filing  
8/5/2014Gary G BenanavDirectorSell12,694$70.82$898,989.08View SEC Filing  
8/5/2014Sara E WadeVPSell20,000$70.44$1,408,800.00View SEC Filing  
8/4/2014David A NortonVPSell1,276$71.02$90,621.52View SEC Filing  
8/1/2014Maura C BreenDirectorSell12,694$69.94$887,818.36View SEC Filing  
6/13/2014George PazCEOSell681,508$71.21$48,530,184.68View SEC Filing  
3/11/2014Keith EblingVPSell25,721$78.69$2,023,985.4922,222View SEC Filing  
3/10/2014Patrick McnameeCOOSell68,425$78.28$5,356,309.0012,421View SEC Filing  
3/10/2014Steven MillerVPSell12,664$77.96$987,285.4421,417View SEC Filing  
3/7/2014Keith EblingVPSell295,367$77.29$22,828,915.4328,460View SEC Filing  
1/9/2014Nicholas LahowchicDirectorSell7,650$72.00$550,800.0024,903View SEC Filing  
12/26/2013Nicholas LahowchicDirectorSell12,694$70.00$888,580.0024,903View SEC Filing  
11/5/2013Mahon Thomas MacDirectorSell10,251$63.20$647,863.2039,881View SEC Filing  
9/9/2013Maura C BreenDirectorSell10,527$64.12$674,991.24View SEC Filing  
9/4/2013Woodrow Myers, Jr.DirectorSell7,128$64.66$460,896.489,698View SEC Filing  
7/19/2013Nicholas LahowchicDirectorSell20,377$66.26$1,350,180.02View SEC Filing  
6/11/2013Woodrow A Myers JrDirectorSell1,750$62.57$109,497.50View SEC Filing  
5/28/2013Woodrow A Myers JrDirectorSell2,000$63.75$127,500.00View SEC Filing  
5/15/2013Jeffrey HallCFOSell13,307$61.13$813,456.91View SEC Filing  
5/8/2013Woodrow A Myers JrDirectorSell13,462$61.22$824,143.64View SEC Filing  
5/1/2013Keith J EblingEVPSell59,494$59.58$3,544,652.52View SEC Filing  
4/30/2013Patrick McnameeCOOSell271,972$59.65$16,223,129.80View SEC Filing  
3/14/2013Mahon Thomas P MacDirectorBuy5,000$59.58$297,900.00View SEC Filing  
9/4/2012Jeffrey HallCFOSell75,000$62.81$4,710,750.00View SEC Filing  
8/8/2012Edward B IgnaczakEVPSell115,466$59.33$6,850,597.78View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Express Scripts (NASDAQ ESRX) News Headlines

Source:
DateHeadline
Jeff Ubbens ValueAct Picks Up 2 New Stocks in 4th QuarterJeff Ubben's ValueAct Picks Up 2 New Stocks in 4th Quarter
finance.yahoo.com - February 20 at 8:03 AM
Inside Rx Pets Savings Program Helps Pet Parents Save BigInside Rx Pets Savings Program Helps Pet Parents Save Big
finance.yahoo.com - February 20 at 8:03 AM
Express Scripts (ESRX) to Release Quarterly Earnings on TuesdayExpress Scripts (ESRX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 5:10 AM
Express Scripts (ESRX) Stock Rating Lowered by BidaskClubExpress Scripts (ESRX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 18 at 3:04 PM
[$$] Irish drugmaker Horizon Pharma raises painkiller price to $3,000 in US[$$] Irish drugmaker Horizon Pharma raises painkiller price to $3,000 in US
finance.yahoo.com - February 16 at 8:03 AM
Zacks Investment Research Upgrades Express Scripts (ESRX) to BuyZacks Investment Research Upgrades Express Scripts (ESRX) to Buy
www.americanbankingnews.com - February 14 at 12:24 PM
Express Scripts Holding (ESRX) Receives Consensus Rating of "Hold" from BrokeragesExpress Scripts Holding (ESRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 11:48 AM
What Stands Between Bezos, Buffett, and Dimon and a Health-Care FixWhat Stands Between Bezos, Buffett, and Dimon and a Health-Care Fix
finance.yahoo.com - February 14 at 7:51 AM
Pharma Gets the Worst of Both Drug-Pricing WorldsPharma Gets the Worst of Both Drug-Pricing Worlds
finance.yahoo.com - February 13 at 3:32 PM
Express Scripts Holding (ESRX) Sees Large Drop in Short InterestExpress Scripts Holding (ESRX) Sees Large Drop in Short Interest
www.americanbankingnews.com - February 10 at 2:02 AM
$25.12 Billion in Sales Expected for Express Scripts Holding (ESRX) This Quarter$25.12 Billion in Sales Expected for Express Scripts Holding (ESRX) This Quarter
www.americanbankingnews.com - February 7 at 6:04 AM
Express Scripts Reduces Employers Annual Prescription Drug Spending Growth Rate to Historic Low in 2017Express Scripts Reduces Employers' Annual Prescription Drug Spending Growth Rate to Historic Low in 2017
finance.yahoo.com - February 6 at 3:32 PM
Secret Discounts Kept Soaring Drug Bills Down, Says MiddlemanSecret Discounts Kept Soaring Drug Bills Down, Says Middleman
finance.yahoo.com - February 6 at 3:32 PM
Jeff Auxier Comments on Express ScriptsJeff Auxier Comments on Express Scripts
finance.yahoo.com - February 6 at 3:31 PM
Inside Rx Provides Savings on Influenza MedicationsInside Rx Provides Savings on Influenza Medications
finance.yahoo.com - February 5 at 3:30 PM
Express Scripts CIO Neal Sample Has Been Promoted To COOExpress Scripts' CIO Neal Sample Has Been Promoted To COO
finance.yahoo.com - February 5 at 3:30 PM
Express Scripts Holding (ESRX) Expected to Post Earnings of $2.09 Per ShareExpress Scripts Holding (ESRX) Expected to Post Earnings of $2.09 Per Share
www.americanbankingnews.com - February 5 at 11:18 AM
An Rx for Health Care? - BarronsAn Rx for Health Care? - Barron's
www.barrons.com - February 4 at 7:44 AM
BidaskClub Lowers Express Scripts (ESRX) to BuyBidaskClub Lowers Express Scripts (ESRX) to Buy
www.americanbankingnews.com - February 3 at 8:12 PM
Leerink Swann Comments on Express Scripts Holdings Q1 2018 Earnings (ESRX)Leerink Swann Comments on Express Scripts Holding's Q1 2018 Earnings (ESRX)
www.americanbankingnews.com - February 2 at 9:10 AM
Predicted Gross Margin Pressure, EPS Erosion Turn Bernstein Bearish On Express ScriptsPredicted Gross Margin Pressure, EPS Erosion Turn Bernstein Bearish On Express Scripts
finance.yahoo.com - February 2 at 7:35 AM
RBC Likes Express Scripts After Sharp Pullback - BenzingaRBC Likes Express Scripts After 'Sharp' Pullback - Benzinga
www.benzinga.com - January 31 at 3:32 PM
Express Scripts (ESRX) Downgraded by Sanford C. BernsteinExpress Scripts (ESRX) Downgraded by Sanford C. Bernstein
www.americanbankingnews.com - January 30 at 7:28 PM
Nasdaq 100 Movers: ESRX, WDAYNasdaq 100 Movers: ESRX, WDAY
www.nasdaq.com - January 30 at 3:32 PM
Express Scripts (ESRX) Names Neal Sample as COO; Christine Houston to Retire - StreetInsider.comExpress Scripts (ESRX) Names Neal Sample as COO; Christine Houston to Retire - StreetInsider.com
www.streetinsider.com - January 27 at 7:40 AM
Express Scripts Holding (ESRX) Short Interest UpdateExpress Scripts Holding (ESRX) Short Interest Update
www.americanbankingnews.com - January 27 at 3:16 AM
Express Scripts dispute over cyber security disclosure heads to SEC - St. Louis Business JournalExpress Scripts dispute over cyber security disclosure heads to SEC - St. Louis Business Journal
www.bizjournals.com - January 25 at 3:33 PM
Express Scripts (ESRX) Given a $86.00 Price Target at MizuhoExpress Scripts (ESRX) Given a $86.00 Price Target at Mizuho
www.americanbankingnews.com - January 24 at 11:52 PM
Express Scripts: Buy In Slowly, But Buy In - Seeking AlphaExpress Scripts: Buy In Slowly, But Buy In - Seeking Alpha
seekingalpha.com - January 23 at 2:41 PM
Express Scripts Clashes With Investor Over Cyber-Risk DisclosureExpress Scripts Clashes With Investor Over Cyber-Risk Disclosure
finance.yahoo.com - January 23 at 2:41 PM
Zacks: Brokerages Anticipate Express Scripts Holding (ESRX) Will Announce Quarterly Sales of $25.12 BillionZacks: Brokerages Anticipate Express Scripts Holding (ESRX) Will Announce Quarterly Sales of $25.12 Billion
www.americanbankingnews.com - January 21 at 6:44 AM
Express Scripts Holding (ESRX) Receives Average Rating of "Hold" from AnalystsExpress Scripts Holding (ESRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 20 at 11:48 AM
Super Savings: Inside Rx Expands Its Prescription Savings Program, Offers Discounts on 100 Brand Name MedicationsSuper Savings: Inside Rx Expands Its Prescription Savings Program, Offers Discounts on 100 Brand Name Medications
finance.yahoo.com - January 17 at 9:37 AM
Express Scripts Holding Company Announces Fourth Quarter and Full Year 2017 Earnings Conference CallExpress Scripts Holding Company Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
feeds.benzinga.com - January 15 at 2:37 PM
Express Scripts 90-Day Analysis of Opioid Management Positive - NasdaqExpress Scripts 90-Day Analysis of Opioid Management Positive - Nasdaq
www.nasdaq.com - January 15 at 9:39 AM
Express Scripts 90-Day Analysis of Opioid Management PositiveExpress Scripts 90-Day Analysis of Opioid Management Positive
finance.yahoo.com - January 15 at 9:39 AM
Express Scripts (ESRX) Rating Reiterated by SunTrust BanksExpress Scripts (ESRX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - January 14 at 12:38 AM
Express Scripts Holding (ESRX) Short Interest Down 15.5% in DecemberExpress Scripts Holding (ESRX) Short Interest Down 15.5% in December
www.americanbankingnews.com - January 13 at 2:04 AM
Express Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,449 SharesExpress Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,449 Shares
www.americanbankingnews.com - January 12 at 6:58 PM
Express Scripts Holding Expected to Post Q1 2018 Earnings of $1.93 Per Share (ESRX)Express Scripts Holding Expected to Post Q1 2018 Earnings of $1.93 Per Share (ESRX)
www.americanbankingnews.com - January 11 at 10:00 AM
A Look At The Fair Value Of Express Scripts Holding Company (NASDAQ:ESRX)A Look At The Fair Value Of Express Scripts Holding Company (NASDAQ:ESRX)
finance.yahoo.com - January 10 at 9:49 AM
Express Scripts Accredo Earns Renewed URAC Specialty Pharmacy AccreditationExpress Scripts' Accredo Earns Renewed URAC Specialty Pharmacy Accreditation
finance.yahoo.com - January 10 at 9:49 AM
Inside Rx En Español: Company Launches Spanish Language Website for Consumers Seeking Discounts on Prescription MedicationsInside Rx En Español: Company Launches Spanish Language Website for Consumers Seeking Discounts on Prescription Medications
finance.yahoo.com - January 10 at 9:49 AM
Express Scripts Hits 80-Plus Relative Strength Rating BenchmarkExpress Scripts Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 9 at 5:11 PM
Express Scripts CEO Says PBM Is a Value CreatorExpress Scripts CEO Says PBM Is a Value Creator
finance.yahoo.com - January 9 at 5:11 PM
Express Scripts CEO Welcomes Opportunity to Work With AmazonExpress Scripts CEO Welcomes Opportunity to Work With Amazon
finance.yahoo.com - January 9 at 5:11 PM
Why Express Scripts Holding Company Broke Out in December - Motley FoolWhy Express Scripts Holding Company Broke Out in December - Motley Fool
www.fool.com - January 8 at 10:01 AM
Why Express Scripts Holding Company Broke Out in DecemberWhy Express Scripts Holding Company Broke Out in December
www.fool.com - January 7 at 7:23 AM
Express Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,448 SharesExpress Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,448 Shares
www.americanbankingnews.com - January 4 at 7:56 PM
Express Scripts (ESRX) Research Coverage Started at Evercore ISIExpress Scripts (ESRX) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - January 4 at 5:12 PM

SEC Filings

Express Scripts (NASDAQ:ESRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Express Scripts (NASDAQ ESRX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.